HS
HighVista Strategies Portfolio holdings
AUM
$272M
This Quarter Return
-7.72%
1 Year Return
+24.34%
3 Year Return
+176.43%
5 Year Return
+271.23%
10 Year Return
+682.63%
AUM
$157M
AUM Growth
+$157M
(+25%)
Cap. Flow
+$45.4M
Cap. Flow
% of AUM
28.88%
Top 10 Holdings %
Top 10 Hldgs %
45.06%
Holding
108
New
39
Increased
16
Reduced
23
Closed
22
Top Buys
| 1 |
Visa
V
|
$9.12M |
| 2 |
Mastercard
MA
|
$8.65M |
| 3 |
Fiserv
FI
|
$8.45M |
| 4 |
PayPal
PYPL
|
$5.87M |
| 5 |
Fidelity National Information Services
FIS
|
$3.85M |
Top Sells
| 1 |
XLNX
Xilinx Inc
XLNX
|
$5.13M |
| 2 |
INFO
IHS Markit Ltd. Common Shares
INFO
|
$4.35M |
| 3 |
NUAN
Nuance Communications, Inc.
NUAN
|
$3.59M |
| 4 |
CONE
CyrusOne Inc Common Stock
CONE
|
$3.47M |
| 5 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
$1.99M |
Sector Composition
| 1 | Healthcare | 44.39% |
| 2 | Technology | 25.46% |
| 3 | Financials | 19.54% |
| 4 | Consumer Discretionary | 2.88% |
| 5 | Communication Services | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
BridgeBio Pharma
BBIO
$9.91B
| $866K | 0.55% |
85,300
+51,450
| +152% | +$522K |
|
52
Xenon Pharmaceuticals
XENE
$2.99B
| $856K | 0.54% |
27,992
-34,914
| -56% | -$1.07M |
|
53
C4 Therapeutics
CCCC
$182M
| $843K | 0.54% |
34,760
+3,267
| +10% | +$79.2K |
|
54
Travere Therapeutics
TVTX
$1.75B
| $838K | 0.53% |
32,501
-21,602
| -40% | -$557K |
|
55
Acadia Pharmaceuticals
ACAD
$4.34B
| $826K | 0.53% |
+34,116
| New | +$826K |
|
56
Galapagos
GLPG
$2.06B
| $819K | 0.52% |
+13,209
| New | +$819K |
|
57
Merus
MRUS
$5.04B
| $803K | 0.51% |
30,388
-23,452
| -44% | -$620K |
|
|
BCYC
58
Bicycle Therapeutics
BCYC
$492M
| $803K | 0.51% |
+18,298
| New | +$803K |
|
|
MRTX
59
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $802K | 0.51% |
9,753
+517
| +6% | +$42.5K |
|
60
Rocket Pharmaceuticals
RCKT
$358M
| $764K | 0.49% |
48,191
+1,278
| +3% | +$20.3K |
|
|
ITOS
61
DELISTED
iTeos Therapeutics
ITOS
| $734K | 0.47% |
22,812
-11,675
| -34% | -$376K |
|
|
NGM
62
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $705K | 0.45% |
+46,243
| New | +$705K |
|
|
CBAY
63
DELISTED
Cymabay Therapeutics
CBAY
| $645K | 0.41% |
+207,307
| New | +$645K |
|
64
Beam Therapeutics
BEAM
$1.9B
| $636K | 0.4% |
11,102
-2,436
| -18% | -$140K |
|
65
Gossamer Bio
GOSS
$587M
| $608K | 0.39% |
+70,042
| New | +$608K |
|
|
NVTA
66
DELISTED
Invitae Corporation
NVTA
| $602K | 0.38% |
75,472
+30,505
| +68% | +$243K |
|
67
Edgewise Therapeutics
EWTX
$1.54B
| $579K | 0.37% |
+59,733
| New | +$579K |
|
68
Relmada Therapeutics
RLMD
$48.8M
| $577K | 0.37% |
+21,381
| New | +$577K |
|
|
TPTX
69
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $565K | 0.36% |
+21,037
| New | +$565K |
|
70
IDEAYA Biosciences
IDYA
$2.26B
| $554K | 0.35% |
49,527
+8,908
| +22% | +$99.6K |
|
71
Natera
NTRA
$23B
| $547K | 0.35% |
13,448
+2,409
| +22% | +$98K |
|
72
Biomea Fusion
BMEA
$114M
| $504K | 0.32% |
+112,918
| New | +$504K |
|
73
United Therapeutics
UTHR
$17.7B
| $477K | 0.3% |
2,657
-3,609
| -58% | -$648K |
|
74
Prothena Corp
PRTA
$452M
| $474K | 0.3% |
12,953
-15,125
| -54% | -$553K |
|
|
BLU
75
DELISTED
BELLUS Health Inc.
BLU
| $448K | 0.28% |
+65,174
| New | +$448K |
|